Radioimmunotherapy in Oncology: Overview of the Last Decade Clinical Trials

The specific irradiation of tumors with selective radiolabeled antibodies constitutes an attractive therapeutic approach. Consequent preclinical research has been conducted by both biologists to identify pertinent targets and to select corresponding antibodies (mAb) and by radiochemists to radiolabe...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Aurélie Rondon, Jacques Rouanet, Françoise Degoul
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	RIT hematologic cancers solid cancers antibody fragments PRIT radionuclides Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/84b9eabcb1ee4a7680734cf6d002e4ee
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:84b9eabcb1ee4a7680734cf6d002e4ee
record_format	dspace
spelling	oai:doaj.org-article:84b9eabcb1ee4a7680734cf6d002e4ee2021-11-11T15:35:32ZRadioimmunotherapy in Oncology: Overview of the Last Decade Clinical Trials10.3390/cancers132155702072-6694https://doaj.org/article/84b9eabcb1ee4a7680734cf6d002e4ee2021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/21/5570https://doaj.org/toc/2072-6694The specific irradiation of tumors with selective radiolabeled antibodies constitutes an attractive therapeutic approach. Consequent preclinical research has been conducted by both biologists to identify pertinent targets and to select corresponding antibodies (mAb) and by radiochemists to radiolabel mAbs. These numerous preclinical investigations have ascertained the therapeutic interest of radioimmunotherapy (RIT) protocols in mice models. Here, we summarize the clinical studies that have been performed the last decade, including clinical trials (phases I, II, and III), prospective and retrospective studies, and cases series. We thereby reported 92 clinical studies. Among them, 62 concern the treatment of hematological malignancies, and 30 concern solid tumors. For hematologic diseases, the analysis was complex due to the high discrepancy of therapeutic strategies (first-line therapy, consolidation, stem cell transplantation conditioning) as well as the high variety of malignancies that were treated. The clinical studies from the last decade failed to expand anti-CD20 RIT indications but confirmed that RIT using radiolabeled anti-CD20 remains a pertinent choice for patients with relapse follicular lymphomas. For solid tumors, the positive benefit of RIT is more mitigated, apart for few malignancies that can be treated locally. Clinical trials also demonstrated the potential of some antibody formats, such as F(ab′)<sub>2</sub>, which has already been approved by the China State FDA under the trend name Licartin®. Despite disparate results, mAb fragments are an interesting prospect for the improvement of RIT efficiency as well as for pretargeted strategies that delay the injection of radioactive treatments from the mAb ones.Aurélie RondonJacques RouanetFrançoise DegoulMDPI AGarticleRIThematologic cancerssolid cancersantibody fragmentsPRITradionuclidesNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5570, p 5570 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	RIT hematologic cancers solid cancers antibody fragments PRIT radionuclides Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	RIT hematologic cancers solid cancers antibody fragments PRIT radionuclides Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Aurélie Rondon Jacques Rouanet Françoise Degoul Radioimmunotherapy in Oncology: Overview of the Last Decade Clinical Trials
description	The specific irradiation of tumors with selective radiolabeled antibodies constitutes an attractive therapeutic approach. Consequent preclinical research has been conducted by both biologists to identify pertinent targets and to select corresponding antibodies (mAb) and by radiochemists to radiolabel mAbs. These numerous preclinical investigations have ascertained the therapeutic interest of radioimmunotherapy (RIT) protocols in mice models. Here, we summarize the clinical studies that have been performed the last decade, including clinical trials (phases I, II, and III), prospective and retrospective studies, and cases series. We thereby reported 92 clinical studies. Among them, 62 concern the treatment of hematological malignancies, and 30 concern solid tumors. For hematologic diseases, the analysis was complex due to the high discrepancy of therapeutic strategies (first-line therapy, consolidation, stem cell transplantation conditioning) as well as the high variety of malignancies that were treated. The clinical studies from the last decade failed to expand anti-CD20 RIT indications but confirmed that RIT using radiolabeled anti-CD20 remains a pertinent choice for patients with relapse follicular lymphomas. For solid tumors, the positive benefit of RIT is more mitigated, apart for few malignancies that can be treated locally. Clinical trials also demonstrated the potential of some antibody formats, such as F(ab′)<sub>2</sub>, which has already been approved by the China State FDA under the trend name Licartin®. Despite disparate results, mAb fragments are an interesting prospect for the improvement of RIT efficiency as well as for pretargeted strategies that delay the injection of radioactive treatments from the mAb ones.
format	article
author	Aurélie Rondon Jacques Rouanet Françoise Degoul
author_facet	Aurélie Rondon Jacques Rouanet Françoise Degoul
author_sort	Aurélie Rondon
title	Radioimmunotherapy in Oncology: Overview of the Last Decade Clinical Trials
title_short	Radioimmunotherapy in Oncology: Overview of the Last Decade Clinical Trials
title_full	Radioimmunotherapy in Oncology: Overview of the Last Decade Clinical Trials
title_fullStr	Radioimmunotherapy in Oncology: Overview of the Last Decade Clinical Trials
title_full_unstemmed	Radioimmunotherapy in Oncology: Overview of the Last Decade Clinical Trials
title_sort	radioimmunotherapy in oncology: overview of the last decade clinical trials
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/84b9eabcb1ee4a7680734cf6d002e4ee
work_keys_str_mv	AT aurelierondon radioimmunotherapyinoncologyoverviewofthelastdecadeclinicaltrials AT jacquesrouanet radioimmunotherapyinoncologyoverviewofthelastdecadeclinicaltrials AT francoisedegoul radioimmunotherapyinoncologyoverviewofthelastdecadeclinicaltrials
_version_	1718435192247418880

Radioimmunotherapy in Oncology: Overview of the Last Decade Clinical Trials

Ejemplares similares